GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenith Drugs Ltd (NSE:ZENITHDRUG) » Definitions » ROE %

Zenith Drugs (NSE:ZENITHDRUG) ROE % : 19.72% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenith Drugs ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zenith Drugs's annualized net income for the quarter that ended in Mar. 2024 was ₹84 Mil. Zenith Drugs's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ₹425 Mil. Therefore, Zenith Drugs's annualized ROE % for the quarter that ended in Mar. 2024 was 19.72%.

The historical rank and industry rank for Zenith Drugs's ROE % or its related term are showing as below:

NSE:ZENITHDRUG' s ROE % Range Over the Past 10 Years
Min: 23.99   Med: 31.29   Max: 33.84
Current: 28.04

During the past 4 years, Zenith Drugs's highest ROE % was 33.84%. The lowest was 23.99%. And the median was 31.29%.

NSE:ZENITHDRUG's ROE % is ranked better than
94.12% of 953 companies
in the Drug Manufacturers industry
Industry Median: 4.67 vs NSE:ZENITHDRUG: 28.04

Zenith Drugs ROE % Historical Data

The historical data trend for Zenith Drugs's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Drugs ROE % Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24
ROE %
33.84 29.83 32.74 23.99

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24
ROE % - - - 53.56 19.72

Competitive Comparison of Zenith Drugs's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Drugs's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's ROE % distribution charts can be found below:

* The bar in red indicates where Zenith Drugs's ROE % falls into.


;
;

Zenith Drugs ROE % Calculation

Zenith Drugs's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=95.928/( (177.216+622.642)/ 2 )
=95.928/399.929
=23.99 %

Zenith Drugs's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=83.746/( (226.496+622.642)/ 2 )
=83.746/424.569
=19.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Zenith Drugs  (NSE:ZENITHDRUG) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=83.746/424.569
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(83.746 / 1244.208)*(1244.208 / 1237.6395)*(1237.6395 / 424.569)
=Net Margin %*Asset Turnover*Equity Multiplier
=6.73 %*1.0053*2.915
=ROA %*Equity Multiplier
=6.77 %*2.915
=19.72 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=83.746/424.569
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (83.746 / 117.078) * (117.078 / 127.576) * (127.576 / 1244.208) * (1244.208 / 1237.6395) * (1237.6395 / 424.569)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7153 * 0.9177 * 10.25 % * 1.0053 * 2.915
=19.72 %

Note: The net income data used here is two times the semi-annual (Mar. 2024) net income data. The Revenue data used here is two times the semi-annual (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Zenith Drugs ROE % Related Terms

Thank you for viewing the detailed overview of Zenith Drugs's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Drugs Business Description

Traded in Other Exchanges
N/A
Address
K. No. 72 / 5, Village Muradpura, NA Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, and Capsules. It is also into Generic Medicines.

Zenith Drugs Headlines

No Headlines